Crizotinib Approval Expanded for Advanced Lung Cancer



The FDA has approved uses of the targeted therapy crizotinib (Xalkori®) for patients with advanced lung cancer whose tumors have alterations in the ROS1 gene.



Source link

Comments are closed.